Features

Features

Demystifying the immune system with the help of AI-ML

Immunotherapy drugs continue to gain momentum across a growing range of disease areas with blockbusters such as MSD's Keytruda (pembrolizumab)…

Features

From Nobel to next-gen: Sweden’s quiet life sciences ascent

Features

New US biotech hubs showing potential amid onshoring request

Features

Pharma R&D set to endure despite rising MFN costs

Features

NewCo licensing models are tipping deals in favour of China’s biotechs

Features

The Baltics: a region punching above its weight on the global life sciences stage

Features

Magazine: China’s CGT edge

Features

What does the EU Data Act mean for businesses?

Features

As US funding falters, mRNA cancer vaccine pioneers face new hurdles

Features

Podcast: key trials and trends from ESC Congress 2025

Features

Cell and gene therapies on correction course but not sinking

Features

Animal testing alternatives to dominate, but not overnight

Annabel Kartal Allen

Features

Magazine: Big biopharma take on the ADC challenge

Features

Accelerating diagnosis and drug development with better managed datasets

Features

A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm

Features

Podcast: US tariff news and Q2 earnings influence pharma trends

Robert Barrie and Manasi Vaidya

Features

Europe’s cannabis pharmaceuticals market matures amid cautious investment

Catherine Longworth

Features

Targeting energy expenditure: the next wave of obesity drugs

Frankie Fattorini

Features

Synthetic rescue: Insmed explores a new frontier in genetic therapeutics

Catherine Longworth

Features

Can rare disease research in the US thrive under the new administration?

Features

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Frankie Fattorini

Features

Why can’t the US figure out weight loss drug prices?

Features

How will RFK Jr’s American dream for vaccines play out?

Features

EHDS regulation will depend on strong patient confidence

Features

From discovery to delivery: making therapies reach patients faster

Features

Magazine: Are regulators keeping pace with AI adoption in clinical trials?

Features

Can pharma tariffs “Make America Manufacture Again”?

Frankie Fattorini

Features

Power of collaboration more pertinent than ever says pharma experts

Features

Newborn screening strategy needs modernising as HHS disbands advisory committee

Features

Pharma’s AI prospects get nudged into the future with EU’s AI act

Features

Are regulators keeping pace with AI adoption in clinical trials?

Awards

Introducing the Pharmaceutical Technology Excellence Awards 2025

Features

Entering the era of prenatal gene therapies

Features

Magazine: The GLP-1 shortage is over. What’s next for compounders?

Features

Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market

Features

FDA layoffs and priority review programme’s lapse disrupt rare disease pipeline

Features

Podcast: What’s next for pharma tariffs?

Manasi Vaidya , Jenna Philpott and Abigail Beaney

Features

The GLP-1 drug shortage is over. What’s next for the compounders?

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close